Dr Iain Thomas

Dr Iain Thomas - Head of Life Sciences

Iain is Head of Life Sciences at Cambridge Enterprise.

Cambridge Enterprise’s Life Sciences product portfolio includes alemtuzumab (Sanofi), breast cancer markers (Brevagen) and mouse touch screen chambers (Campden Instruments). Recent spin-outs include Mission Therapeutics, Cambridge Epigenetix, XO1 Therapeutics, Z-factor and Phoremost. Recent transactions include licences in fields as diverse as therapeutics, diagnostics, biofuels, IVF and epigenetics and the sale of XO1 to Johnson & Johnson. Iain led discussions with GSK in respect of the University of Cambridge–GSK open innovation drug discovery initiative based at the SBC.

+44 (0)1223 332830 iain.thomas@enterprise.cam.ac.uk